Evidence map›Paper›PMID 31539622›Full record

Trial reportDiabetes & metabolism2020

Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10).

M S Capehorn, A-M Catarig, J K Furberg, A Janez, H C Price, S Tadayon, B Vergès, M Marre

3 registry-linked trialsAbstract readClinical Trial, Phase IIIComparative StudyMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Diabetes & metabolism, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT03191396. Cited by 187 papers, 21 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
187citing papers in PubMed, 21 pooled it
25.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03191396 phase3completed

Efficacy and Safety of Semaglutide 1.0 mg Once-weekly Versus Liraglutide 1.2 mg Once-daily as add-on to 1-3 Oral Anti-diabetic Drugs (OADs) in Subjects With Type 2 Diabetes

Ran2017Enrolled577Registered outcomes41Posted comparisons3ConditionsDiabetes, Diabetes Mellitus, Type 2Armsliraglutide, semaglutide
Open the trial in the graph
NCT06894784 phase3recruitingstarted 2025, after this paper: background citation

Semaglutide And Empagliflozin Combination Therapy Added To Automated Insulin Delivery In Adults With Type 1 Diabetes (SEMPA)

Ran2025Enrolled36Registered outcomes13Posted comparisons0ConditionsDiabetes Type 1ArmsIntervention Period 1: Semaglutide + Empagliflozin, Intervention Period 2: Semaglutide + Empagliflozin Placebo, Intervention Period 3: Semaglutide Placebo + Empagliflozin, Intervention Period 4: Semaglutide Placebo + Empagliflozin Placebo
PMID 20616619PMID 36942888PMID 29246950PMID 27295427PMID 28854085PMID 25388240PMID 24947583PMID 27633186PMID 30833170PMID 29397376PMID 10233049PMID 19925391other papers from this trial
Open the trial in the graph
NCT07284511 phase2 / phase3recruitingstarted 2026, after this paper: background citation

Fully Closed-Loop Glucose Control in Adults With Type 1 Diabetes Using Tirzepatide: a Randomized, Multi-center, Open-label, Non-inferiority, Parallel Trial

Ran2026Enrolled105Registered outcomes35Posted comparisons0ConditionsT1D, T1DM, T1DM - Type 1 Diabetes Mellitus, Type 1 DiabetesArmsCarbohydrate Counting, No Meal Announcement, Tandem Control-IQ Automated Insulin Delivery System (with Dexcom G7 CGM), Tirzepatide
PMID 39745353PMID 39601745PMID 29246950PMID 27295427PMID 27633186PMID 34170647PMID 39794615PMID 29747423PMID 27621531PMID 27118163PMID 21346182PMID 18252903other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

187 citing papers in PubMed, 21 syntheses or guidelines pooled it, 391 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Meta-analysis of the Effect of Semaglutide on Blood Pressure in Obese Populations.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2025 · on this map
    Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Pooled it
  19. Pooled it
  20. Pooled it

127 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 4 countries.

M S CapehornRotherham Institute for Obesity, Clifton Medical Centre, S65 1DA Rotherham, South Yorkshire, UK. Electronic address: mcapehorn@yahoo.co.uk.
A-M CatarigNovo Nordisk A/S, DK-2860 Søborg, Denmark.
J K FurbergNovo Nordisk A/S, DK-2860 Søborg, Denmark.
A JanezDepartment of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia.
H C PriceWest Hampshire Community Diabetes Service, SO43 7NG Lyndhurst, UK.
S TadayonNovo Nordisk A/S, DK-2860 Søborg, Denmark.
B VergèsCHU, 21000 Dijon, France.
M MarreClinique Ambroise Paré, 27, boulevard Victor-Hugo, 92200 Neuilly-sur-Seine, France.
Novo Nordisk (Denmark) · DKCHU Dijon Bourgogne · FRClinique Ambroise Paré · FRLjubljana University Medical Centre · SIRotherham General Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsSUSTAIN 10 compared the efficacy and safety of the anticipated most frequent semaglutide dose (1.0mg) with the current most frequently prescribed liraglutide dose in Europe (1.2mg), reflecting clinical practice.

methodsIn this phase 3b, open-label trial, 577 adults with type 2 diabetes (HbA

resultsMean HbA

conclusionSemaglutide was superior to liraglutide in reducing HbA

Indexed as

Administration, OralAgedBlood GlucoseDiabetes Mellitus, Type 2Drug Therapy, CombinationFemaleGlucagon-Like PeptidesGlycated HemoglobinHumansHypoglycemic AgentsInjections, SubcutaneousLiraglutideMaleMetforminMiddle AgedSemaglutideBlood GlucoseGlucagon-Like PeptidesGlycated HemoglobinHypoglycemic AgentsLiraglutideMetforminSemaglutideGlucagon-like peptide-1 receptor agonistGlycaemic controlLiraglutideSemaglutideSUSTAINType 2 diabetes

Identifiers

PMID31539622
OpenAlexW2973758715

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.